The inaugural FierceMedTech Fierce 15—a call for nominations

Send us your nominations for the 2017 FierceMedTech Fierce 15.

Each year, our crop of Fierce 15 honorees includes an increasing number of nontraditional device players. From Glooko and Propeller Health—both digital disease management platforms—to image analysis players Arterys and Zebra Medical, the way we think about medical technology and devices has changed considerably.

So much so that the FDA rolled out a new program this summer aimed at creating a new regulatory pathway to accommodate digital health software that poses a lower risk than traditional medical devices.

“FDA’s traditional approach to medical devices is not well suited to these [digital health products]. We need to make sure our approach to innovative products with continual updates and upgrades is efficient and that it fosters, not impedes, innovation,” said FDA Commissioner Scott Gottlieb at the time.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

In a nod to the rise of new medical technologies, FierceMedicalDevices became FierceMedTech earlier this year. Now, we are selecting our first medtech Fierce 15—and we need your help. We are looking for medtech pioneers at the cutting edge of their field, adapting current technology, or creating entirely new systems to treat disease.

Know a medtech startup transforming the way a disease is diagnosed or treated? Let us know in the nomination form below. Check out last year’s honorees to see the type of companies we're looking for. Nominations close on Oct. 16.

The nominees should meet the following criteria:

  • Companies must be privately held, not publicly traded.
  • Companies should be working on treatments for human diseases.
  • Executives must be available for interviews and agree to keep their status in our selection process confidential until the final list is announced.

 

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.